By Justin Petrone

GenMark Diagnostics is planning to introduce a number of array-based tests in coming years and is working on an automated, next-generation instrument, according to a May 13 filing with the US Securities and Exchanges Commission.

The filing came days after the firm reported that its first-quarter sales nearly doubled over the prior year, driven by an increase in instrument placements.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.